Cargando…

Pulmonary Hypertension in Glycogen Storage Disease Type II

Detalles Bibliográficos
Autores principales:	Li, Hui-Ping, Xie, Wan-Mu, Huang, Xu, Lu, Xin, Zhai, Zhen-Guo, Zhan, Qing-Yuan, Wang, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987515/ https://www.ncbi.nlm.nih.gov/pubmed/29786057 http://dx.doi.org/10.4103/0366-6999.232792

Ejemplares similares

The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases
por: Heiner-Fokkema, M. Rebecca, et al.
Publicado: (2020)

Cognitive Dysfunction in Patients with Pulmonary Hypertension
por: Yuan, Ping, et al.
Publicado: (2022)

Altered electrical properties in skeletal muscle of mice with glycogen storage disease type II
por: Nagy, Janice A., et al.
Publicado: (2022)

Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases
por: Pursell, Natalie, et al.
Publicado: (2018)

The value of speckle-tracking echocardiography in identifying right heart dysfunction in patients with chronic thromboembolic pulmonary hypertension
por: Li, Ai-Li, et al.
Publicado: (2018)

Liver transplantation in glycogen storage disease type I
por: Boers, Susanna JB, et al.
Publicado: (2014)

Liver Transplantation for Glycogen Storage Disease Type IV
por: Liu, Min, et al.
Publicado: (2021)

Novel AGL variants in a patient with glycogen storage disease type IIIb and pulmonary hypertension caused by pulmonary veno-occlusive disease: A case report
por: Shindo, Akito, et al.
Publicado: (2023)

Reply to Sun et al.: circGASP: A New Clinical Biomarker for Idiopathic Pulmonary Hypertension?
por: Sun, Yuan-Yuan, et al.
Publicado: (2021)

A simpler noninvasive method of predicting markedly elevated pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension
por: Zhai, Ya‐Nan, et al.
Publicado: (2022)

Glycogen storage diseases: An update
por: Gümüş, Ersin, et al.
Publicado: (2023)

A glycogen storage disease type 1a patient with type 2 diabetes
por: Sun, Yi, et al.
Publicado: (2022)

More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Ning, Dong, et al.
Publicado: (2020)

Glycogen storage disease type VI with a novel PYGL mutation: Two case reports and literature review
por: Zhan, Qian, et al.
Publicado: (2021)

Glycogen storage disease type IV: a case report.
por: Lee, K. Y., et al.
Publicado: (1998)

The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI
por: Grünert, Sarah Catharina, et al.
Publicado: (2021)

Glycogen storage disease type 1a in the Ohio Amish
por: Scott, Ethan M., et al.
Publicado: (2022)

Choice of diagnostic method for liver‐type glycogen storage disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2022)

French recommendations for the management of glycogen storage disease type III
por: Wicker, Camille, et al.
Publicado: (2023)

Minimally invasive surgery for glycogen storage disease combined with inflammatory bowel disease: A case report
por: Wan, Jian, et al.
Publicado: (2021)

Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)
por: Farmakis, Ioannis T., et al.
Publicado: (2022)

Effect of COVID-19 in Pulmonary Hypertension
por: Jha, Ajay Kumar
Publicado: (2022)

A novel mutation in the glycogen synthase 2 gene in a child with glycogen storage disease type 0
por: Soggia, Ana Priscila, et al.
Publicado: (2010)

Next-generation glycogen storage diseases
por: Derks, Terry G. J., et al.
Publicado: (2018)

Biomarkers in Glycogen Storage Diseases: An Update
por: Molares-Vila, Alberto, et al.
Publicado: (2021)

Can Pulmonary Arterial Compliance Be a Prognostic Marker for Pulmonary Hypertension?
por: Wu, Yanjuan, et al.
Publicado: (2023)

S2.1 Enzyme replacement therapy (ERT) in Glycogen Storage Disease Type II: the first treatment developed
por: Angelini, Corrado, et al.
Publicado: (2011)

Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy
por: Marzorati, Mauro, et al.
Publicado: (2012)

Novel Mutation in the Feline GAA Gene in a Cat with Glycogen Storage Disease Type II (Pompe Disease)
por: Rakib, Tofazzal Md, et al.
Publicado: (2023)

ON THE DIFFERING APPEARANCE OF INTRANUCLEAR AND CYTOPLASMIC GLYCOGEN IN LIVER CELLS IN GLYCOGEN STORAGE DISEASE
por: Sheldon, H., et al.
Publicado: (1962)

Learning curve and analysis of curative effects after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Hong, Cheng, et al.
Publicado: (2023)

Geneotype and phenotype in 20 patients with glycogen storage disease type Ia
por: Liang, Cuili, et al.
Publicado: (2013)

Characterization of a canine model of glycogen storage disease type IIIa
por: Yi, Haiqing, et al.
Publicado: (2012)

Molecular diagnosis of glycogen storage disease type I: a review
por: Beyzaei, Zahra, et al.
Publicado: (2019)

Kidney and Metabolic Phenotypes in Glycogen Storage Disease Type-I Patients
por: Aoun, Bilal, et al.
Publicado: (2020)

Successful pregnancy in a woman with glycogen storage disease type 6
por: Grünert, Sarah Catharina, et al.
Publicado: (2021)

The potential of dietary treatment in patients with glycogen storage disease type IV
por: Derks, Terry G. J., et al.
Publicado: (2020)

Estimation of Health Utility Scores for Glycogen Storage Disease Type Ia
por: Kruger, Eliza, et al.
Publicado: (2023)

CBLN2 rs2217560 was Associated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus
por: Huang, Can, et al.
Publicado: (2018)

Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Weatherald, Jason, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l2471brnh4lsckh6nnqgfqliku